Wave Life Sciences

WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.

Type
Public
HQ
Cambridge, US
Founded
2012
Size (employees)
41 (est)
Wave Life Sciences was founded in 2012 and is headquartered in Cambridge, US

Wave Life Sciences Office Locations

Wave Life Sciences has office in Cambridge
Cambridge, US

Wave Life Sciences Metrics

Wave Life Sciences Summary

Market capitalization

$721 M

Closing share price

$28.1
Wave Life Sciences's current market capitalization is $721 M.

Wave Life Sciences Financials

Wave Life Sciences's revenue is $152 K in FY, 2015
FY, 2015

Revenue

$152 K

Net Income

$-19.2 M

Wave Life Sciences Market Value History

Wave Life Sciences Online Presence

Wave Life Sciences Company Life

You may also be interested in